personalized medicine

This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.

A new precision medicine approach is making life sweeter for infants unable to metabolize milk sugar.

Analyzing the whole genome sequences of more than 18,000 tumors, researchers catalog nearly 60 new patterns of mutations that could inform cancer treatment.

A study probes how genetic duplications that can swell protein length influence human traits such as height and kidney function.

Some of the blood specimens collected in the United States for the NIH’s All of Us research program starting on January 2, 2020, have antibodies against SARS-CoV-2.

Sensors encapsulated with oral chemotherapy drugs help patients and physicians keep track of treatments.

Meet some of the people featured in the July/August 2019 issue of The Scientist.

Not only can artificial intelligence revolutionize healthcare, it could help restore the doctor-patient relationship.

The three-dimensional cell cultures are still in the development phase, but researchers are excited about their use to predict patients’ responses to various treatment options.

Eric Topol, founder and director of Scripps Research Translational Institute and Reading Frames author, discusses the future of the doctor-patient bond in an era of artificial intelligence–driven medicine.

This month’s Profilee, Dana-Farber Cancer Institute researcher Stuart Orkin, talks about treating kids with cancer and other blood disorders.

Comparing the cells of cancer patients who did and did not respond to the immunotherapy could reveal biomarkers to predict who should receive it in the first place.

The expression of a slew of genes in psychiatric patients closely tracks pain intensity and predicts future emergency room visits, according to a study.

See how a computational pipeline uses next-generation sequencing data to identify genetic alterations that produce cancer-specific antigens.

The field is young, but predicting antigens produced by patients’ malignant cells could yield successful treatments for individuals with a range of cancer types.

There are currently more than two dozen ongoing Phase 1 and Phase 2 trials using different vaccine platforms such as DNA, RNA, synthetic long peptides, and dendritic cells.